Drug Development & Transactional Deals for Neurodegenerative Disorders

This poster was originally presented by Anmol Grover at GTCBio’s CNS Diseases Summit 2017.

Neurodegenerative disorders (NDDs) impact a significant number of the US and the global population and are the leading cause of disability and morbidity in the US.  There is a long history of failed attempts to develop effective therapies, and currently, there are no treatments that can prevent, slow down, or cure NDD.

Here we present an in-depth analysis of the current development pipeline for AD, PD, HD, and ALS by phase and mechanism of action with the focus on symptomatic versus disease-modifying approaches. Furthermore, we provide insights on the challenges in drug development for NDD and how they can be addressed.

Click to download the poster